A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Why did I choose diagnostics?
I am an optimist. I see possibility in everything we do. Today we are delivering clinical utility—real value—by changing clinical practice.
Real People,
Real Science,
Real Answers.
BONNIE H. ANDERSON
Chief Executive Officer and
Chairman of the Board
This is the Age of Evidence.
Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek.

Veracyte gives patients a clearer path for the future.

We are leading in the Age of Evidence.

LEARN MORE >
our impact
LATEST NEWS
New data published in The Lancet Respiratory Medicine show that the Envisia Genomic Classifier improves diagnosis of IPF
learn more >
LATEST NEWS
Veracyte Launches Next-Generation Percepta® Genomic Sequencing Classifier for improved lung cancer diagnosis
learn more >
WATCH
Bonnie Anderson, Veracyte CEO interview with Bill Vick/PF Warriors about the Envisia Genomic Classifier and plans to transform IPF/ILD diagnosis

WATCH NOW >


latest news
news and updates
Veracyte Aims to Expand Diagnostics Reach with $50M NanoString Deal
Xconomy
Dec 3, 2019
Genomic Sequencing Classifier May Improve Management of Indeterminate Pulmonary Nodules
Healio
Oct 30, 2019
Nasal Swab Could Help Gauge Smokers’ Odds for Lung Cancer
U.S. News & World Report
Oct 24, 2019